Voyager Therapeutics
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $4,014 | $3,165 | $2,593 | $15,336 |
Gross Profit | 4,014 | 3,165 | 2,593 | 15,336 |
EBITDA | -24,676 | -23,545 | -26,991 | -26,368 |
EBIT | -26,422 | -24,453 | -27,923 | -27,417 |
Net Income | -24,694 | -24,473 | -27,937 | -27,426 |
Net Change In Cash | 4,014 | 3,165 | 2,593 | 15,336 |
Free Cash Flow | -19,666 | -25,842 | -33,433 | -30,889 |
Cash | 48,408 | 35,769 | 43,314 | 65,300 |
Basic Shares | 61,824 | 60,547 | 59,496 | 58,691 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $40,374 | $80,001 | $250,008 | $40,907 |
Gross Profit | -91,900 | 80,001 | 157,836 | 40,907 |
EBITDA | -115,517 | -59,606 | 138,179 | -44,646 |
EBIT | -119,577 | -64,337 | 133,738 | -50,837 |
Net Income | -119,721 | -65,002 | 132,330 | -46,408 |
Net Change In Cash | 40,374 | 80,001 | 250,008 | 40,907 |
Cost of Revenue | -18,738 | |||
Free Cash Flow | -135,063 | -18,831 | 74,663 | -15,000 |
Cash | 65,300 | 71,367 | 68,802 | 98,959 |
Basic Shares | 58,691 | 57,667 | 44,569 | 38,356 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | -$0.40 |
2026-06-30 | -$0.40 |
2026-03-31 | -$0.47 |
2025-12-31 | -$0.47 |